zomikos 4 mg/5 ml infúzny koncentrát
vipharm s.a., poľsko - kyselina zoledrónová - 87 - varia i
tolnexa 20 mg/ml infúzny koncentrát
krka, d.d., novo mesto, slovinsko - docetaxel - 44 - cytostatica
capecitabine fair-med 500 mg filmom obalené tablety
fair-med healthcare gmbh, nemecko - kapecitabín - 44 - cytostatica
capecitabine fair-med 150 mg filmom obalené tablety
fair-med healthcare gmbh, nemecko - kapecitabín - 44 - cytostatica
pemetrexed mylan 1000 mg
mylan ireland limited, Írsko - pemetrexed - 44 - cytostatica
pemetrexed mylan 500 mg
mylan ireland limited, Írsko - pemetrexed - 44 - cytostatica
pemetrexed mylan 100 mg
mylan ireland limited, Írsko - pemetrexed - 44 - cytostatica
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastické činidlá - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastické činidlá - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
jemperli
glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.